Healthy Life Blog

GlaxoSmithKline could reap a £2.6billion windfall from the swine flu pandemic, it emerged yesterday.

Sales of the drugs giant’s Relenza inhaler, used to treat the symptoms of the virus, are expected to top £600million, bossAndrew Wittyconfirmed.

And this figure could be boosted by a further £1billion-£2billion once deliveries of vaccination for the H1N1 strain of the bug begin in September, according to analysts.

Read more:http://www.dailymail.co.uk/money/article-1201491/Swine-flu-pandemic-drugs-giant-GlaxoSmithKline-2-6bn-boost.html?ITO=1490#ixzz0MXbXPPTX

Related posts:

1. Md. Reports Fourth Swine Flu Death, Eighth in Region
2. Swine Flu Death Toll 816: WHO
3. How to: Save a heart attack victim